KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Change in Accured Expenses (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 16 years of Change in Accured Expenses data on record, last reported at -$211000.0 in Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 109.53% year-over-year to -$211000.0; the TTM value through Dec 2025 reached -$285000.0, down 119.48%, while the annual FY2025 figure was -$285000.0, 119.48% down from the prior year.
  • Change in Accured Expenses reached -$211000.0 in Q4 2025 per RIGL's latest filing, down from $2.2 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $5.9 million in Q2 2022 and bottomed at -$4.1 million in Q1 2025.
  • Average Change in Accured Expenses over 5 years is $13100.0, with a median of $81000.0 recorded in 2021.
  • The widest YoY moves for Change in Accured Expenses: up 414.45% in 2022, down 6759.02% in 2022.
  • A 5-year view of Change in Accured Expenses shows it stood at $1.2 million in 2021, then crashed by 259.97% to -$2.0 million in 2022, then surged by 164.34% to $1.3 million in 2023, then skyrocketed by 75.1% to $2.2 million in 2024, then plummeted by 109.53% to -$211000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were -$211000.0 in Q4 2025, $2.2 million in Q3 2025, and $1.9 million in Q2 2025.